Regadenoson

Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS[1][2].

Product Specifications

CAS Number

[313348-27-5]

Product Name Alternative

CVT-3146

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Regadenoson.html

Purity

99.59

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(N=C2)C(N)=NC(N4C=C(C=N4)C(NC)=O)=N3)O1

Molecular Formula

C15H18N8O5

Molecular Weight

390.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Trochu JN, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol. 2003 Jan;41 (1) :132-9. |[2]Jackson S, et al. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016 Feb;126 (3) :433-9.